HOME >> BIOLOGY >> NEWS
Heart failure: Intervention possibilities from imaging programmed cell loss

RESTON, Va.Using a nuclear medicine technique and molecular imaging to "see" programmed cell lossthe body's normal way of getting rid of unneeded or abnormal cellsmay help in early identification of those individuals who are at risk of developing heart failure, say researchers in the April Journal of Nuclear Medicine.

"Our study indicates that it is feasible to noninvasively identify cell lossor apoptosisin heart failure patients using annexin A5 imaging," explained Leo Hofstra, director of cardiovascular imaging at the University Hospital of Maastricht in the Netherlands. "Such a strategy may offer a new possibility for studying interventions to minimize damage to the heart muscle," he added. "This research is significant since cell loss is potentially reversible and earlier intervention could delay the development of cardiomyopathy or heart muscle disease," noted Hofstra. He indicated that additional research is needed since the study was performed on a small group of heart patients.

"Heart failure is a major health care problem," said Hofstra, "and researchers are looking at novel ways to improve patient care." With heart failure, a person's heart no longer pumps sufficient blood to the body's organs. Nearly 5 million Americans are living with heart failurea long-term condition that tends to gradually worsenand 550,000 new cases are diagnosed each year.

Researchers attached a radioactive substance to annexin A5, a protein that binds to dying cells, said Hofstra. They then used nuclear imaging that produces three-dimensional computer-reconstructed images to reveal information about both structure and function to measure the amount of annexin A5 absorbed. Annexin A5 bound to the damaged heart muscle. "We discovered that higher uptake was uptake with a worse outcome. Cell death is one of the biological events that worsens left ventricular events," said Hofstra.

"Our results indicate that heart muscle cell death is an acti
'"/>

Contact: Maryann Verrillo
mverrillo@snm.org
703-653-6773
Society of Nuclear Medicine
3-Apr-2007


Page: 1 2

Related biology news :

1. Hearts of male and female rainbow trout are different
2. Heart intervention doesnt outweigh medicine in study
3. International Society for Heart and Lung Transplantation 27th Annual Meeting and Scientific Sessions
4. Heart rhythm genes possible factors in SIDS
5. Hearts or tails?
6. Heart smart: new drug improves blood flow
7. Heart has enough oxygen to survive hypothermia, CPR crucial
8. Defusing a time bomb: Heart attack risk-detection technology developed at UH
9. Heart failure wall stress drops 38% with moderate thyroid hormone therapy
10. New studies released at the Heart Rhythm Societys Annual Meeting
11. Molecular testing impact: Heart transplant patients benefit from new technology, easier monitoring

Post Your Comments:
(Date:5/20/2013)... resistant to the antibiotic colistin are also commonly ... body, according to a study in mBio ... Society for Microbiology. Cross-resistance to colistin and host ... body against bacterial attack, could mean that patients ... with a crippled immune response. Colistin is a ...
(Date:5/20/2013)... Science Foundation (NSF) planning grant will help establish the ... program of the University of Illinois at Urbana-Champaign and ... will be devoted to research in drying moist, porous ... and paper products; chemical products; textiles; and biopharmaceuticals," said ... science and human nutrition and the Illinois site director. ...
(Date:5/19/2013)... strain of electricity-producing bacteria that can grow using hydrogen ... as its sole source of carbon. Researchers at ... the 113th General Meeting of the American Society for ... production solely on hydrogen," says Amit Kumar, a researcher ... part of the Lovley Lab Group at the university. ...
Breaking Biology News(10 mins):Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3NSF approves planning grant for Center for Advanced Research in Drying 2
(Date:5/21/2013)... Raleigh, NC (PRWEB) May 21, 2013 ... and financial services company for clinical trials, announced ... Aggregate Spend Solutions, LLC. Clinverse’s ClinPay® FLS ... automated investigator payment process. SpendMD ™, ... only complete solution for tracking and reporting transfer ...
(Date:5/21/2013)... , May 21, 2013 According ... Research ( http://www.transparencymarketresearch.com ) "Biochip Products and Services Market ... - U.S. Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018," ... 2011 and is expected to grow at a CAGR ... estimated value of USD 4.7 billion in 2018. ...
(Date:5/21/2013)... 21, 2013 Many have long discussed ... to acne. Recently physicians from Clinical Psychiatry.com ... on the skin, and suggested using hypnotherapy ... chemicals produced from stress that cause acne. , Doctors ... feelings acne brings about, stress causes changes in the ...
(Date:5/21/2013)... ROCKVILLE, Md. , May 21, 2013 /PRNewswire/ ... "Phase 1 study of margetuximab (MGAH22), an Fc-modified ... solid tumors expressing the HER2 oncoprotein," will be ... American Society of Clinical Oncology during the Developmental ... June 3 at 4:15 – 4:30 PM.  The ...
Breaking Biology Technology:Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5Adult Acne Treatment, Probiotic Action Explains How Hypnotherapy and Probiotics May Cure Various Skin Conditions 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
Cached News: